跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

MERZ PHARMACEUTICALS GMBH

首页临床试验发起方与机构MERZ PHARMACEUTICALS GMBH

MERZ PHARMACEUTICALS GMBH

ACTIVE

8427 Plymouth Ln, Frisco, Texas, 美国www.radiesse.deSubsidiary101–250 名员工成立于: 1908-01-01

隶属于 Merz Pharma Gmbh & Co. Kgaa

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

178

106 进行中

药物批准

28

批准总数

监管机构

5

监管机构数

成立时间

1908

概览

试验阶段分布

阶段

试验数

占比

1 期

56

31.5%

3 期

36

20.2%

2 期

12

6.7%

4 期

7

3.9%

不适用

3

1.7%

Unknown

1

0.6%

试验状态分布

进行中（未招募）

105

59.0%

已完成

63

35.4%

尚未招募

1

0.6%

招募中

2

1.1%

终止

5

2.8%

Unknown

1

0.6%

撤回

1

0.6%

相关临床试验

该机构主办的试验（178）

Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by stroke or traumatic brain injury.

Jul 2024445 名受试者

A clinical study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy.

Mar 2024130 名受试者

Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by stroke or traumatic brain injury.

进行中（未招募）

Jan 2023600 名受试者

A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods

Oct 202240 名受试者

Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by stroke or traumatic brain injury.

进行中（未招募）

Aug 2022600 名受试者

Open-label, multicenter, uncontrolled, randomized, post market clinical follow-up (PMCF) study to confirm effectiveness and safety of Belotero® Revive in facial skin revitalization and photo-damaged skin treatment

Jul 2021159 名受试者

A Study to Investigate the Efficacy and Safety of NT201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

进行中（未招募）

Jul 202175 名受试者

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

Feb 202178 名受试者

第 1 页，共 23 页

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

6

药物批准

EMA

European Medicines Agency

2

药物批准

CANADA

Health Canada

4

药物批准

SFDA

Saudi Food and Drug Authority

2

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

14

药物批准

近期批准

XEOMIN 50 U Vial

XEOMIN 100 U Vial

Compound Heparin Sodium and Allantoin Gel

Compound Heparin Sodium and Allantoin Gel

Botulinum Toxin Type A for Injection

Botulinum Toxin Type A for Injection

Ornithine Aspartate Injection

AXURA 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

AXURA 10 mg COMPRIMIDOS RECUBIERTOS CON PELICULA

资讯

暂无资讯文章

本页目录

概览
相关临床试验178
药物批准28
资讯

返回机构列表